

R371
"S465"

m. seligmann and w. h. hitzig editors

**primary
immuno-
deficiencies**

inserm symposium 16

50623

PRIMARY IMMUNODEFICIENCIES

Proceedings of the International Symposium on Primary Immunodeficiencies
held in Abbaye de Royaumont (France), 18-20 July, 1980.

Sponsored by the Institut National de la Santé et de la Recherche Médicale.


Editors: M. SELIGMANN
W.H. HITZIG



INSERM SYMPOSIUM No. 16



INSTITUT NATIONAL DE LA SANTÉ
ET DE LA RECHERCHE MÉDICALE



1980

ELSEVIER/NORTH-HOLLAND BIOMEDICAL PRESS
AMSTERDAM · NEW YORK · OXFORD

© ELSEVIER/NORTH-HOLLAND BIOMEDICAL PRESS—1980

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior permission of the copyright owner.

ISBN Series: 0 7204 0653 6

ISBN Volume: 0-444-80296-7

Publishers:

ELSEVIER/NORTH-HOLLAND BIOMEDICAL PRESS
335 JAN VAN GALENSTRAAT, P.O. BOX 211
AMSTERDAM, THE NETHERLANDS

Sole distributors for the USA and Canada:

ELSEVIER NORTH HOLLAND INC.
52 VANDERBILT AVENUE,
NEW YORK, N.Y. 10017

Library of Congress Cataloging in Publication Data

International Symposium on Primary Immunodeficiencies,
Abbaye de Royaumont, France, 1980.
Primary immunodeficiencies.

(INSERM symposium ; no. 16)

Bibliography: p.

Includes index.

1. Immunological deficiency syndromes--Congresses. 2. Immunological deficiency syndromes--Animal models--Congresses. I. Seligmann, Maxime, 1927- II. Hitzig, Walter H. III. Institut national de la santé et de la recherche médicale. IV. Title. V. Series: Institut national de la santé et de la recherche médicale.

INSERM symposium ; no. 16.

RC606.I59 1980 616.07'9 80-25785

ISBN 0-444-80296-7

FOREWORD

Human primary immunodeficiencies have been, for the past 25 years, one of the most productive areas of research in clinical immunology. Detailed studies of these patients have provided new concepts and important insights into our understanding of the immune system and, conversely, advances in basic immunology have been rapidly applied to clinical investigation. These syndromes represent real experiments of nature and constitute a field par excellence where clinical and basic immunology are closely linked and mutually beneficial.

Two international symposia on primary immunodeficiencies have been previously held in the United States thanks to the vigorous impulse of R.A. Good and under the auspices of the National Foundation. Together with the attempts at classification of these diseases undertaken by a group of experts appointed by WHO, these meetings have provided valuable opportunities to expand our knowledge. During the recent years, new immunological and clinical findings have accumulated and the biochemical study of the enzymatic defects responsible for some immunodeficiency syndromes has opened a new and important field of investigation. It seemed therefore appropriate to hold a new symposium and to gather basic and clinical immunologists, biochemists and pediatricians devoted to the study of immunodeficiencies. We thought that this meeting should take place in Europe, and we are grateful to INSERM for sponsoring it.

M. SELIGMANN

W. HITZIG

LIST OF PARTICIPANTS

Dr. F. AIUTI
Istituto di Clinica Medica Generale
Universita di Roma
00161 ROMA (Italie)

Dr. J.F. BACH
Hôpital Necker - INSERM U 25
149 rue de Sèvres
75015 PARIS (France)

Dr. Marie Anne BACH
Hôpital Necker - INSERM U 25
149 rue de Sèvres
75015 PARIS (France)

Dr. J. J. BALLET
Laboratoire d'Immunochimie et
d'Immunopathologie - INSERM U 108
Hôpital Saint Louis
75475 PARIS (France)

Dr. M. BLAESE
National Cancer Institute
Bldg 10
N.I.H
BETHESDA, MD 20014 (U.S.A.)

Dr. Rebecca BUCKLEY
Duke University Medical Center
Box 2898
DURHAM, N.C. 27710 (U.S.A.)

Dr. D.A. CARSON
Division of Rheumatology
Dept of Clinical Research
Scripps Clinic and Research Foundation
Keeney Park
1066 Torrey Pines Road
LA JOLLA, CA. 92037 (U.S.A.)

Dr. M.D. COOPER
Cellular Immunobiology Unit
Department of Pediatrics and
Microbiology
University of Alabama in Birmingham
School of Medicine
BIRMINGHAM, ALA. 35295 (U.S.A.)

Dr. A. FISCHER
INSERM U 132
Hôpital des Enfants Malades
149, rue de Sèvres
75030 PARIS Cedex 15 (France)
Presently :
Tumor immunology Unit
University College Medical School
Hospital
University Street
LONDON WC1E 6JJ (U.K.)

Dr. H.D. FLAD
Abt. f. Mikrobiologie der Universität
Oberer Eselsberg
7900 ULM (B.R.D.)

Dr. R. GEHA
Division of Allergy
The Children's Hospital Medical Center
300 Longwood ave
BOSTON, MA. 02115 (U.S.A.)

Dr. R.A. GOOD
Memorial Sloan Kettering Cancer Center
410 East 68th street
NEW YORK, N.Y. (U.S.A.)

Dr. C. GRISCELLI
INSERM U 132
Hôpital des Enfants Malades
149, rue de Sèvres
75730 PARIS Cedex 15 (France)

Dr. A. HAYWARD
Department of Immunology
Institute of Child Health
30 Guilford street
LONDON WC1 (U.K.)
Presently :
Dept of Pediatrics
University of Colorado Medical Center
4200 East Ninth Ave
DENVER, Colo. 80220 (U.S.A.)

Dr. Rochelle HIRSCHHORN
Dept of Medicine
New York University Medical Center
Medical Center
550 First Ave
NEW YORK, N.Y. 10016 (U.S.A.)

Dr. W. HITZIG
Universitätskinderklinik
Steinwiesstr. 75
CH 8032 - ZURICH (Suisse)

Dr. P. KINCADE
Sloan Kettering Institute
145 Boston Post Rd
RYE, N.Y. 10580 (U.S.A.)

Dr. H.G. KUNKEL
Rockefeller Institute
66th street and York ave
NEW YORK, N.Y. 10021 (U.S.A.)

Dr. P. LAGRANGE
Institut Pasteur
25, rue du Dr Roux
75015 PARIS (France)

Dr. S. LEVIN
KAPLAN HOSPITAL
P.O.B. 1
REHOVOT (Israel)

Dr. D.W. MARTIN Jr
Laboratory of Molecular Genetics
University of California
School of Medicine
SAN FRANCISCO, CA. 94143 (U.S.A.)

Dr. F. MELCHERS
Basel Institute for Immunology
487 Grenzacherstr.
CH-4005 BASEL (Suisse)

Dr. D. NELSON
Metabolic Branch
National Cancer Institute
N.I.H.
BETHESDA, MD 20014 (U.S.A.)

Dr. H. OCHS
Dept of Pediatrics RD-20
School of Medicine
University of Washington
SEATTLE, WA. 98105 (U.S.A.)

Dr. R.J. O'REILLY
Sloan Kettering Institute
1275 York Ave
NEW YORK, N.Y. 10021 (U.S.A.)

Dr. W. PAUL
Laboratory of Immunology
National Institute of Allergy
and Infectious Diseases Bldg 10
N.I.H.
BETHESDA, MD. 20014 (U.S.A.)

Dr. Delphine PARROTT
Dept of Bacteriology and Immunology
Western Infirmary
GLASGOW G11 6NT (Scotland, U.K.)

Dr. T.A.E. PLATTS MILLS
Clinical Research Centre
Division of Immunological Medicine
Watford Road
HARROW, Middlesex HA1 2UJ (U.K.)

Dr. P. QUIE
Dept of Pediatrics and Microbiology
University of Minnesota Medical School
Box 483
MINNEAPOLIS, Minn. 55455 (U.S.A.)

Dr. J.C. RODER
Dept of Microbiology and Immunology
Queens University
KINGSTON, Canada K7L 3N6

Dr. F. ROSEN
Harvard Medical School
The Children's Hospital Medical Center
300 Longwood Ave
BOSTON, MA 02115 (U.S.A.)

Dr. S.F. SCHLOSSMAN
Sidney Farber Cancer Institute
44 Binney Street
BOSTON, MA. 02115 (U.S.A.)

Dr. R.K.B. SCHUURMAN

Dept of Pediatrics
Sophia Children's Hospital
Erasmus University
P.O. Box 70029
3000 LL ROTTERDAM (Hollande)

Dr. J. SCHWABER

Harvard Medical School
The Children's Hospital Medical Center
300 Longwood ave
BOSTON, MA. 02115 (U.S.A.)

Dr. R. SEGER

Universitäts Kinderklinik
Steinwieestr. 75
8032 ZURICH (Suisse)

Dr. J.E. SEEGMILLER

Dept of Medicine (M-013)
University of California
San Diego
LA JOLLA, CA. 92093 (U.S.A.)

Dr. M. SELIGMANN

Laboratoire d'Immunochimie et
d'Immunopathologie - INSERM U 108
Hôpital Saint-Louis
75475 PARIS Cedex 10 (France)

Dr. J.F. SOOTHILL

Department of Immunology
Institute of Child Health
30 Guilford street
LONDON WC1 (U.K.)

Dr. J.W. STOOP

Dept of Pediatrics
University Children's Hospital
Het Wilhelmina Kinderziekenhuis
Nieuwe Gracht 137
UTRECHT (Hollande)

Dr. T.P. STOSSEL

Massachusetts General Hospital
BOSTON, MA 02114 (U.S.A.)

Dr. TOIVANEN

Dept of Medical Microbiology
University of Turku
20520 TURKU 52 (Finlande)
Presently :
Basel Institute for Immunology
487 Grenzacherstr.
CH BASEL 5 (Suisse)

Dr. J.L. TOURAINE

Service de Néphrologie - INSERM U 80
Hopital Edouard Herriot
5, place d'Arsonval
69374 LYON CEDEX 2 (France)

Dr. P. TROTTA

Sloan Kettering Institute
1275 York Ave
NEW YORK, N.Y. 10021 (U.S.A.)

Dr. J.L. VIRELIZIER

INSERM U 132
Hôpital des Enfants Malades
149, rue de Sévres
75730 PARIS Cedex 15 (France)

Dr. T.A. WALDMANN

Chief of Metabolic Branch
National Cancer Institute
N.I.H.
BETHESDA, MD. 20014 (U.S.A.)

Dr. A.D.B. WEBSTER

Clinical Research Center
Watford Road
HARROW, Middlesex HA1 3UJ (U.K.)

Dr. R. WEDGWOOD

Dept of Pediatrics RD 20
School of Medicine
University of Washington
SEATTLE, WA 98195 (U.S.A.)

Dr. B. ZEGERS

Dept of Immunology
Het Wilhelmina Kinderziekenhuis
Nieuwe Gracht 137
3512 LK UTRECHT (Hollande).

CONTENTS

| | |
|--|-----|
| Foreword | V |
| List of Participants | VI |
| ONTOGENY AND DIFFERENTIATION OF HUMAN LYMPHOID CELLS IN THE NORMAL AND IN IMMUNODEFICIENT PATIENTS | |
| IgM production: Normal development and selective deficiency D. Levitt and M.D. Cooper | 3 |
| Immunoglobulin synthesis by cord and maternal blood mononuclear cells and their effect on synthesis by normal adult cells A.P. Knutsen and R.H. Buckley | 13 |
| Development of lymphocyte responses and regulatory mechanisms A. Hayward and J. Kurnick | 23 |
| Regulation of human M component synthesis in hypogamma- globulinemia by anti-idiotypic antibodies R.S. Geha | 29 |
| The significance of immature B cells found in the peripheral blood of patients with late onset hypogammaglobulinaemia T.A.E. Platts-Mills, G.C. de Gast, R.S. Pereira, A.D.B. Webster, G.L. Asherson and S.R. Wilkins | 39 |
| Agammaglobulinemia <i>in vitro</i> ; Lymphoid cell lines and somatic cell hybrids J. Schwaber | 49 |
| Unusual lymphoid cell lines derived from patients with immunodeficient states S.M. Fu, J.N. Hurley, J. M. McCune, H.G. Kunkel and R.A. Good | 59 |
| Variability in the expression of X-linked agammaglobulinemia: The co-existence of classic X-LA (Bruton type) and "common variable immunodeficiency" in the same families R.J. Wedgwood and H.D. Ochs | 69 |
| Role of MHC determinants in immunodeficiency diseases as shown by the "bare lymphocyte syndrome" and by chimeric patients J.L. Touraine, H. Betuel, F. Touraine, N. Philippe, B. Betend and R. Francois | 79 |
| Lymphocyte-membrane abnormalities associated with primary immunodeficiency disease R.K.B. Schuurman, E.W. Gelfand, J.L. Touraine and J.J. van Rood | 87 |
| Auto-antibodies to a B cell subset in patients with the Wiskott-Aldrich syndrome J.C. Brouet, C. Courvalin, A. Chevalier and M. Seligmann | 101 |

| | |
|--|-----|
| Human immunodeficiency states resulting from disorders of T cell maturation and regulation E.L. Reinherz, S.F. Schlossman and F.S. Rosen | 109 |
| Suppressor cells in common variable immunodeficiency T.A. Waldmann, S. Broder, C.K. Goldman, S. Marshall and L. Muul | 119 |
| T cell regulatory function in patients with various immuno- deficiencies as studied by <i>in vitro</i> antibody response of the blood lymphocytes B.J.M. Zegers, C.J. Heijnen, W. Kuis, F. Uytdehaag, J. Roord, J.W. Stoop and R.E. Ballieux | 129 |
| Lymphocyte-mediated cytotoxicity in immunodeficiency patients D.L. Nelson | 141 |
| Induction by gammaglobulin therapy of T and B lymphocyte dysfunctions in the <i>in vitro</i> PWM system A. Durandy, A. Fischer and C. Griscelli | 151 |
| EXPERIMENTAL MODELS OF IMMUNODEFICIENCY | |
| Profound immunologic abnormalities of mice expressing both the <i>xid</i> and <i>nu</i> genes J.J. Mond, J. Cossman, L. Trost, C.T. Hansen, P.K.A. Mongini, S. Kessler, I. Scher and W.E. Paul | 165 |
| T-cell dependent B cell stimulation in the mouse F. Melchers | 173 |
| Hemopoietic cells capable of reconstituting immunodeficient mice P.W. Kincade, G. Lee and C.J. Paige | 179 |
| B cell differentiation in immunodeficient chicks: Origin of stem cells and role of histocompatibility restriction A. Toivanen, P. Toivanen, O. Lassila, O. Vainio and Y. Hirota | 189 |
| Characterization of a murine model for combined immuno- deficiency P.P. Trotta, A. Tedde, M.E. Balis, S. Ikehara, R. Pahwa, E.M. Sordillo, G.F. Brown and R.A. Good | 197 |
| A selective natural killer cell deficiency in man and a mouse model J.C. Roder and T. Haliotis | 207 |
| Intestinal abnormalities and T cell mediated immune responses during <i>Trichinella spiralis</i> infection D.M.V. Parrott, D.F. Manson-Smith and R.G. Bruce | 215 |
| The relation of zinc deficiency to immunologic function in animals and man R.A. Good, G. Fernandes, C. Cunningham-Rundles, S. Cunningham-Rundles, J.A. Garofalo, K.M.K. Rao, G.S. Incefy and T. Iwata | 223 |

METABOLIC BASES OF IMMUNODEFICIENCIES

Metabolic basis of immunodeficiency disorders
R. Hirschhorn and H. Ratech 237

A biochemical genetic approach to the understanding of
immunodeficiency diseases
D.W. Martin, Jr. 251

Deoxypurine metabolism in human lymphocyte subpopulations:
Possible biochemical basis for T cell dysfunction in
ADA and PNP deficiencies
D.A. Carson 261

Possible mechanisms of immunodeficiency disease associated
with hereditary defects in enzymes of purine degradation
J.E. Seegmiller 269

The metabolism of deoxynucleosides by T and B lymphocytes
A.D.B. Webster, M.E. North, M. Rowe and S.M. Johnson 279

Immunologic studies in adenosine deaminase and nucleoside
phosphorylase deficiencies
H.D. Ochs, U.H. Ochs, S.-H. Chen, C.R. Scott
and R.J. Wedgwood 287

Purine nucleoside phosphorylase deficiency: Long-term
clinical, immunological and metabolic follow-up
J.W. Stoop, B.J.M. Zegers, W. Kuis, C.J. Heijnen,
J.J. Roord, M. Duran, S.K. Wadman and G.E.J. Staal 301

DYSFUNCTIONS OF PHAGOCYTES AND MONOCYTES

Immunodeficiency caused by phagocyte disorders
T.P. Stossel 315

Possible genetic control of macrophage functions in relation
to the induction and expression of cell mediated immunity
P.H. Lagrange, B. Hurtrel and P.M. Thickstun 329

Patients with congenital abnormalities of granulocyte
microbicidal function. Clinical and laboratory
observations
P.G. Quie, E.L. Mills, M. Yanai and J. Abramson 339

Impaired functions of lymphocytes and granulocytes in
transcobalamin-II-deficiency and their response to
treatment
R. Seger, J. Galle, A. Wildfeuer, M. Frater-Schroeder,
J. Linnell and W.H. Hitzig 353

Prostaglandin E₂-mediated monocyte suppressive activity -
Role in immunoregulatory disorders
A. Fischer, A. Durandy and C. Griscelli 363

Modification of neutrophil chemotaxis by Levamisole
therapy in primary immunoglobulin deficiencies
R. D'Amelio, P. Rossi, S. Le Moli and F. Aiuti 373

| | |
|--|-----|
| Defective yeast opsonisation: <i>In vitro</i> and <i>in vivo</i> studies J.F. Soothill, B.A.M. Harvey, M.W. Turner, R.J. Levinsky, D. Robertson, D.C.A. Candy and J.F. Mowbray | 383 |
| The cytolytic effector function of monocytes in immuno- deficiency disease R.M. Blaese, A.V. Muchmore, E.C. Lawrence, D.G. Poplack | 391 |
| THERAPEUTIC ASPECTS | |
| Treatment of immunodeficiency syndromes W.H. Hitzig, P.W. Joller, H.J. Pluess and R. Seger | 401 |
| Correction of primary immunodeficiencies by allogeneic bone marrow transplantation R. Parkman, J.M. Rappeport and F.S. Rosen | 413 |
| Fetal tissue transplants for severe combined immuno- deficiency - Their limitations and functional potential R.J. O'Reilly, N. Kapoor and D. Kirkpatrick | 419 |
| Split chimerism in severe combined immunodeficiency patients lacking genotypically identical siblings H.-D. Flad, S.F. Goldmann, D. Niethammer, A.J. Ulmer, J. Colombani and E. Kleihauer | 435 |
| Conditions for successful bone marrow transplantation in severe osteopetrosis J.-J. Ballet and R. Moutier | 445 |
| The clinical use of thymic factors in immunodeficiency diseases J.-F. Bach, M. Dardenne, P. Lesavre, P. Lefrancier and J. Choay | 455 |
| The interferon system in immunodeficiency and deficiency of the interferon system S. Levin and T. Hahn | 465 |
| Interferon administration as an immunoregulatory and anti-microbial treatment in children with defective interferon secretion J.-L. Virelizier and C. Griscelli | 473 |
| POSTER PRESENTATIONS | |
| T cell subsets analyzed by monoclonal antibodies in primary immunodeficiencies F.P.D. Tuy, M.A. Bach, A. Durandy and C. Griscelli | 487 |
| Inheritance of transcobalamin II (TCII) in two families with TC II deficiency and related immunodeficiency M. Fräter-Schröder, M. Sacher and W.H. Hitzig | 493 |
| Immunologic studies in 21 patients with the hyper IgE syndrome R.H. Buckley | 495 |

| | |
|---|-----|
| Serum IgE and IgG antibody response to <i>Candida albicans</i> and tetanus toxoid in patients with hyper-IgE-syndrome J.J. Ballet, C. Schmitt, M. Agrapart and D. Buriot | 497 |
| Impaired cell to cell interaction in partial combined immunodeficiency with variable expression of HLA antigens C. Griscelli, A. Durandy, J.L. Virelizier, J. Hors, V. Lepage and J. Colombani | 499 |
| B cell reconstitution following marrow grafting for SCID A.R. Hayward and S. Murphy | 505 |
| BCG'osis A.D.B. Webster | 507 |
| Improvement of interstitial pneumonia and natural killer activity after thymopoietin pentapeptide (TP-5) therapy in a child with severe combined immunodeficiency M.C. Sirianni, I. Quinti, M. Fiorilli and F. Aiuti | 511 |
| Generalized ECHO-11 virus infection in X-linked agammaglobulinemia: Successful treatment with large doses of modified gamma globulin given intravenously H.D. Ochs, P.J. Mease, R.J. Wedgwood and S.H. Fischer | 513 |
| Defective handling of Mannan by monocytes in two patients with chronic candidiasis A. Fischer, L. Pichat, M. Audinot and C. Griscelli | 515 |
| Combined immunodeficiency with hyper - IgA and IgE and terminal malignant histiocytosis of lung Z.T. Handzel, S. Levin, A. Kenan, M. Muggia-Sulam and E. Orkon | 519 |
| CONCLUDING REMARKS | |
| Immunodeficiencies 1980. A summary and analysis of the international conference on the immunodeficiency diseases R.A. Good and J. Finstad | 523 |
| Author index | 575 |

...
**ONTOGENY AND DIFFERENTIATION OF
HUMAN LYMPHOID CELLS IN
THE NORMAL AND IN
IMMUNODEFICIENT PATIENTS**

IGM PRODUCTION: NORMAL DEVELOPMENT AND SELECTIVE DEFICIENCY

D. Levitt* and M. D. Cooper

Cellular Immunobiology Unit, Lurleen B. Wallace Tumor Institute, Departments of Pediatrics and Microbiology, University of Alabama in Birmingham, Birmingham, Alabama 35294 and *Department of Pediatrics, University of Chicago, Chicago, Illinois 60649

INTRODUCTION

Immunoglobulin molecules possess several characteristics that distinguish them from the vast array of cellular proteins. By virtue of their insertion into the cell membrane of B lymphocytes, they behave as receptor molecules that can relay messages to the internal milieu of a cell. When actively secreted from a plasma cell, they can combine with specific antigens and enact effector functions that neutralize both foreign and self reactivity. Immunoglobulins can also bind passively to immune and non-immune cells via their Fc region and alter the function of such cells. They can bind complement components and amplify the destruction of foreign antigens or cells as well as initiate disease processes in the host organism.

The diversity of immunoglobulin molecules remains one of the most intriguing problems in immunology. It is now well established that most information encoding immunoglobulin chains is present in the genome of germ cells¹⁻³. In such cells, genes coding for the variable and constant regions of both heavy and light chains are well separated on different chromosomes. During development, specific recombinatorial events occur that transpose a single V_L or V_H gene into juxtaposition with a specific J(joining) gene (Figure 1). The V-J complexes are then approximated with C_L or C_H genes, forming transcriptional units for complete light and heavy chains, respectively^{4,5}. The same V_H J_H genes can then integrate with different constant region genes at various stages of B cell development by a "switch recombination" mechanism⁶, thereby providing a mechanism for immunoglobulin class switches.

IgM plays a pivotal role during B cell development and in specific immune responses. It is the first isotype to appear during the ontogeny of B cells⁷ and to be synthesized and secreted in large quantities following primary immunization. B cells possessing IgM appear to be the direct progenitors of B lymphocytes producing all other antibody classes⁸. Phylogenetically, IgM may be the

only antibody detectable in primitive species of animals. IgM production persists to a greater extent than synthesis of other isotypes in most immunodeficiency disorders, and deficiency of IgM is usually associated with severe bacterial infections. In this article, we wish to examine briefly the development, structure and function of IgM and its relationship to other immunoglobulin classes. We will also present immunological information on a patient with severe IgM deficiency and speculate on the relationship of this defect with immunodeficiency disorders affecting other immunoglobulin isotypes.




Fig. 1. Sequence of immunoglobulin gene rearrangements in the development of B cell clone. See text for discussion.

DEVELOPMENT OF IgM

Mu chains can be detected prior to all other heavy chain classes during the ontogeny of every mammal examined thus far. These molecules, devoid of light chains, are initially found only in the cytoplasm of cells designated pre-B cells^{9,10}. Pre-B cells are sequentially generated in fetal liver and bone marrow, and lack surface μ receptors by functional, immunochemical and immunofluorescent criteria^{10,11}. Free μ chains can be released by pre-B cells from both mice and humans, and may be able to modulate events during the early development of the immune system¹⁰.

The absence of functional antibody receptors on pre-B cells may provide an important means for clonal diversification during B cell development. Such cells would not be subject to positive or negative regulation by environmental antigens and pre-B cells expressing a particular V_H gene could then be rapidly and safely expanded. In these cells, combination of μ chains with randomly selected light chains possessing specific V_L regions would create a diverse array of B lymphocytes derived from a single pre-B cell progenitor.

Following V_L - C_L joining, light chain synthesis is initiated and intact 180,000 dalton IgM molecules soon appear on the surface of B cells. These immature IgM^+ B lymphocytes are the direct progenitors of IgD, IgG, IgA and IgE bearing B cells. Initial evidence for this relationship was derived from ontogenetic analysis of chickens, mice, and humans¹²⁻¹⁴ and studies of the suppressive effects of anti- μ antibodies⁸. When neonatal mice or chickens are repeatedly injected with anti- μ antibodies, the development of surface Ig^+ B lymphocytes of all isotypes is inhibited^{15,16}. Cessation of anti- μ treatment permits the generation of normal numbers of sIg^+ B cells.

Early in their development, B lymphocytes possessing IgD, IgG or IgA on their surface may also express IgM^{13,14}. At a specific point during differentiation, three isotypes may be displayed simultaneously on the surface of a B cell¹³, e.g., IgM.IgD.IgG or IgM.IgD.IgA. The persistence of IgM and IgD on such immature cells along with IgG or IgA suggest that long-lived mRNA for μ and δ may exist during certain stages of B cell development.

STRUCTURE OF IgM

Three forms of IgM can be demonstrated during B cell development. Initially pre-B cells synthesize only free μ chains without light chains. B lymphocytes express 180,000 dalton IgM on their surface with two μ and two light chains. Rapidly secreting plasma cells produce 900,000 dalton pentameric antibodies containing 5 IgM monomers that are linked through disulfide bonds by J(joining) chains.

The μ chains synthesized by each of these cells display characteristic structural distinctions. Pre-B μ chains appear smaller than μ chains secreted by plasma cells (65,000 versus 70,000 daltons) and may be relatively poor in carbohydrate¹⁰. μ chains found on the surface of B lymphocytes are larger than secreted μ chains and contain a 30-40 amino acid tail enriched in hydrophobic amino acids and lacking carbohydrate side chains¹⁷⁻¹⁹. Secreted μ chains have a shorter, relatively hydrophilic tail with carbohydrate side chains.